Form 8-K - Current report:
SEC Accession No. 0000950170-25-044353
Filing Date
2025-03-25
Accepted
2025-03-25 16:03:21
Documents
12
Period of Report
2025-03-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K antx-20250325.htm   iXBRL 8-K 43687
2 EX-99.1 antx-ex99_1.htm EX-99.1 172828
  Complete submission text file 0000950170-25-044353.txt   345953

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20250325.xsd EX-101.SCH 26029
14 EXTRACTED XBRL INSTANCE DOCUMENT antx-20250325_htm.xml XML 4911
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 25768239
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)